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Research
Quantum dots (QDs) are semiconductor
nanocrystals approximately 2–100 nm in
diameter. Structurally, they have a metalloid
core and a cap or shell (Dabbousi et al. 1997).
Organic coatings can be added to the surface
to achieve bioavailability or targeting toward
speciﬁc sites. QDs possess unique luminescent
properties (Akerman et al. 2002). One proba-
ble use of QDs is as optimal ﬂuorophores for
in vivo biomedical imaging (Larson et al. 2003;
Morgan et al. 2005). It can also be used to tar-
get speciﬁc cells (e.g., labeling neoplastic cells)
after conjugation with speciﬁc bioactive moi-
eties (Cai et al. 2006; Voura et al. 2004).
Basically, QD cores consist of various metal
complexes. Cadmium–tellurium (CdTe) and
cadmium–selenium (CdSe) cores with zinc
sulﬁde (ZnS) shells represent the newest struc-
tures synthesized and are most commonly seen
in the QD industry (Lim et al. 2003). Our test
material, QD705, has a CdTe core with a ZnS
shell although analyses in our laboratory
revealed 46, 11, and 1% Cd, Se, and Te,
respectively. These nanocrystals are surface
modified with methoxy-polyethylene glycol
(PEG-5000), an inert biologically compatible
polymer. Both Cd and Se are well-known met-
als that are toxic to humans, causing heptatic,
renal, neurologic and/or genetic toxicities
(Bertin and Averbeck 2006; Klaassen and Liu
1997; Umemura 2000; Vinceti et al. 2001).
Te was also reported to cause neuropathy
(Widy-Tyszkiewicz et al. 2002). Exposures to
these toxic elements are likely when degrada-
tion of QD705 occurs in vivo. 
Despite the immense potential for the
medical applications of QDs and the intent
of introducing these nanocrystals into the
human body, we know little about the dispo-
sition [absorption, distribution, metabolism,
elimination (ADME)] and health conse-
quences of QDs in animals and humans
(Hardman 2006; Nel et al. 2006). Three
excellent recent reviews are available on QDs
and nanomaterials in general (Hardman
2006; Maysinger et al. 2006; Nel et al. 2006).
A commonly agreed issue is the lack of
biosafety data for nanomaterials and the need
for human health assessment. The toxicity of
QDs, if present, depends on a variety of fac-
tors related to the physicochemical properties
of the quantum dots, as well as the environ-
mental conditions they are in (Hardman
2006). These include the size, charge, con-
centration, outer coating, and mechanical
stability of the QDs (Hardman 2006). 
A large proportion of the available litera-
ture involves in vitro studies on a number
of cytotoxic parameters. Although some
investigators reported QDs do not appear to
cause toxicity, others demonstrated a variety
of cytotoxic effects (Chen and Gerion 2004;
Hanaki et al. 2003; Hoshino et al. 2004a,
2004b; Jaiswal et al. 2003; Lovric et al. 2005;
Shiohara et al. 2004; Voura et al. 2004). A few
in vivo studies are available in the literature as
well. Akerman et al. (2002) demonstrated they
were able to target the accumulation of ZnS-
capped CdSe QDs in speciﬁc tissues by vary-
ing the coatings. They also reported that QDs
accumulated in both the liver and spleen in
addition to the intended target tissues.
Dubertret et al. (2002) microinjected QD-
micelles into the embryos of the carnivorous
frog Xenopus and reported that the QDs were
stable, nontoxic, and slow to photobleach.
Further, they suggested QD’s lack of interfer-
ence with embryogenesis (Dubertret et al.
2002). Ballou et al. (2004) reported that the
circulating half-lives in mice were approxi-
mately 12–70 min for QD630, QD645, and
QD655. Whole body fluorescence imaging
studies indicated that QD is present in liver,
lymph nodes, and bone marrow for at least a
month after an intravenous (iv) dosing (Ballou
et al. 2004). Hoshino et al. (2004b) incorpo-
rated QDs into the EL-4 cells, then injected
these cells intravenously into the nude mice to
study the fate of the EL-4 cell and QD on the
basis of fluorescence. These investigators
detected QDs in the kidneys, liver, lung, and
spleen for up to 7 days without damage or
toxicity to the mice (Hoshino et al. 2004b).
These pioneering studies elegantly used the
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BACKGROUND: Quantum dots (QDs) are autoﬂuorescent semiconductor nanocrystals that can be
used for in vivo biomedical imaging. However, we know little about their in vivo disposition and
health consequences.
OBJECTIVES: We assessed the tissue disposition and pharmacokinetics of QD705 in mice.
METHODS: We determined quantitatively the blood and tissue kinetics of QD705 in mice after sin-
gle intravenous (iv) injection at the dose of 40 pmol for up to 28 days. Inductively coupled plasma–
mass spectrometry (ICP-MS) measurement of cadmium was the primary method of quantiﬁcation
of QD705. Fluorescence light microscopy revealed the localization of QD705 in tissues.
RESULTS: Plasma half-life of QD705 in mice was short (18.5 hr), but ICP-MS analyses revealed
QD705 persisted and even continued to increase in the spleen, liver, and kidney 28 days after an iv
dose. Considerable time-dependent redistribution from body mass to liver and kidney was apparent
between 1 and 28 days postdosing. The recoveries at both time points were near 100%; all
QD705s reside in the body. Neither fecal nor urinary excretion of QD705 was detected appreciably
in 28 days postdosing. Fluorescence microscopy demonstrated deposition of QD705 in the liver,
spleen, and kidneys. 
CONCLUSION: Judging from the continued increase in the liver (29–42% of the administered dose),
kidney (1.5–9.2%), and spleen (4.8–5.2%) between 1 and 28 days without any appreciable excre-
tion, QD705 has a very long half-life, potentially weeks or even months, in the body and its health
consequences deserve serious consideration.
KEY WORDS: ICP-MS, kinetics, nanoparticles, quantum dot 705, redistribution, mice. Environ
Health Perspect 115:1339–1343 (2007). doi:10.1289/ehp.10290 available via http://dx.doi.org/
[Online 14 June 2007]ﬂuorescence properties of QDs and provided
valuable information regarding the fate of
QDs in the whole animals. As fluorescence
intensity depends on the microenvironment,
studies based on ﬂuorescence are usually quali-
tative in nature. Thus, quantitative pharmaco-
kinetic analyses of QDs in the animals are
needed. In a recent publication, which is not
easily searchable in biomedical databases,
Fischer et al. (2006) reported pharmacokinet-
ics and tissue sequestration and distribution in
male Sprague-Dawley rats of two QDs synthe-
sized in the authors’ own laboratories (Fischer
et al. 2006). Half-lives were determined to be
39–59 min and the QDs were cleared from
the plasma between 0.59 and 1.23 mL/min/kg
(Fischer et al. 2006). The liver took up 40 to
90% of the QDs after 90 min, whereas the
other tissues retained only a small amounts
(Fischer et al. 2006). 
In our present study, we conducted three
types of experiments on a commercially avail-
able quantum dot, QD705: a) we determined
quantitatively the blood and tissue kinetics of
QD705 in mice after single iv injection for up
to 28 days; b) we performed two mass balance
studies at 1 and 28 days after a single iv dos-
ing to see if we may recover quantitatively the
administered dose and to discern the distribu-
tion of QD705; and c) we localized QD705
in major target organs using fluorescence
microscopy.
Materials and Methods 
The nanoparticles, QD705, used in our exper-
iments are commercially available from
Quantum Dot Corporation (Hayward, CA,
USA) as Qtracker 705 nontargeted quantum
dots. Each particle has a CdTe core and ZnS
shell with methoxy-PEG-5000 coating. The
diameter is about 13 nm, and the molecular
weight is 1.5 × 106 g/mol. According to
Quantum Dot Corporation Certificate of
Analysis, 30 November 2005, and Giepmans
et al. (2005), fluorescence of QD705 ranges
from 650 to 750 nm with an emission maxi-
mum around 700–715 nm. Each tube of this
product contained 200 µL of a 2-µM solution
in 50 mM borate buffer, pH 8.3. We pur-
chased 6-week-old male ICR mice from
BioLASCO (Taiwan) and acclimated the mice
for 2 weeks in the animal facilities at the
National Health Research Institutes (NHRI).
All animal treatments and experimental proto-
col for this study were subjected to the review
and approval of the Animal Control
Committee at NHRI. Thus, animal handling
was in accordance with standard animal hus-
bandry practice and regulation; animals were
treated humanely and with regard for allevia-
tion of suffering throughout the study. All
mice in this study were under 12-hr light/dark
cycle, 23 ± 1°C, 39–43% relative humidity;
water and food were available ad libitum. At
the start of the experiments, the mice were
approximately 8 weeks old and weighed
between 32.9 and 38.7 g each. We selected six
mice/time point, randomly, for time-course
studies. We injected each mouse, via tail veins,
with 40 pmol QD705 (20 µl of a 2-µM solu-
tion) in saline; the injection volume was
100 µL/mouse. We chose the iv route to
mimic potential human medical imaging
application and provide cleaner pharmacoki-
netic proﬁles without the complication of the
absorption phase. Serial sacriﬁces (under pen-
tobarbital anesthesia) took place at 1, 4, 24 hr
at 3, 7, 14, and 28 days after dosing of
QD705. At each of these sacriﬁces, we meas-
ured and recorded body weights as well as
organ weights of each animal. Tissue samples
collected at each time point included plasma,
red blood cells (RBCs), liver, lungs, kidneys,
spleen, muscle, thymus, fat, brain, skin (ear)
and bones. Subsequently, we analyzed and
quantiﬁed QD705 in these tissues. To antici-
pate possible further analyses, we saved the
carcass individually with proper identifica-
tion. QD705 analyses were performed on the
basis of quantification of 111Cd concentra-
tions in various tissues using inductively cou-
pled plasma–mass spectrometry (ICP-MS)
(Elan6100; PerkinElmer, Shelton, CT, USA).
Briefly, we dried the tissues at 95 ± 2°C for
16 hr. They were then weighed and liqueﬁed
with 5 mL nitric acid and 1 mL hydrogen per-
oxide and underwent microwave digestion
(Multiwave 3000; Anton Paar GmbH, Graz,
Austria). ICP-MS measurement of Cd (mass =
m/z 111 and 114) was the primary method of
quantification of QD705 in tissues. With
plasma samples, however, fluorescence spec-
troscopy was an additional method for quan-
tification of QD705 (Ballou et al. 2004).
With the ﬂuorescence method, we centrifuged
the heparinized whole blood samples at
1,500 × g (Allegra X-22R centrifuge; Beckman
Coulter, Fullerton, CA, USA) for 15 min at
4°C to isolate the plasma. Fluorescence spec-
troscopic analyses provided ﬂuorescence inten-
sities (FIs) (excitation/emission: 500/705 nm)
of 20% plasma samples and Rhodamine 101
(a positive control). Normalization of these
results with the absorbance at 705 nm was
necessary. We then calculated the ratio for
each plasma sample from the FI/A ratio of
sample over the FI/absorbance ratio of
Rhodamine 101 (Ballou et al. 2004). For
establishing standard curves, we used a range
of concentrations (0.1, 0.2, 0.4, 0.8, 1.6, 3.2,
and 6.4 nM) of QD705 in 20% control
plasma in saline or normal saline. Comparison
of these standard curves was essential to assess
the quenching effect of plasma on fluores-
cence intensity. Samples, in duplicate, were
placed in block 96-well (100 µL/well) for
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Figure 1. Plasma kinetics of QD705 in ICR mice after iv dosing. ICR mice were
injected via tail vein with 40 pmol QD705. QD concentrations in the plasma were
calculated from ﬂuorescene intensity (FI) and Cd concentrations at 1, 4, 24 hr at
3, 7, and 14 days after dosing of QD705. The 28-day data (close to zero) are not
included to provide a better plot to show the initial phase. The data were mean ±
SD of six replicates.
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Figure 2. Tissue kinetics of QD705 in ICR mice after iv dosing. ICR mice were
injected via tail vein with 40 pmol QD705. Serial sacriﬁces were carried out at
1, 4, 24 hr at 3, 7, 14, and 28 days after dosing. Several organs/tissues, including
spleen, liver, kidney, lung, brain, thymus, muscle, bone, fat, RBCs, and skin
were isolated to determine Cd concentrations with ICP-MS. The data were
mean ± SD of six replicates.
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)measuring fluorescence intensity as well as
absorbance. The pharmacokinetic parameters
were analyzed from Cd time-course plasma
concentrations by using WinNonLin software
program (version 3.1; Pharsight, Mountain
View, CA, USA).
Results
Figure 1 provides the comparative results of
plasma kinetics of QD705 in mice based on
ICP-MS analyses for 111Cd and florescence
spectroscopy. As shown in Figure 1, the time-
course curves based on two different analyti-
cal methods are comparable. The plasma
kinetics of QD705 (Figure 1) revealed that its
clearance from the blood was 2.3 mL/hr/kg.
In about a week, plasma QD705 level was
down to the background level. From the
plasma Cd concentration versus time data, we
calculated the plasma half-life to be 18.5 hr.
QD705 did not appear to have any specific
afﬁnity toward RBCs. 
Initial attempts of tissue analyses of
QD705 using ﬂuorescence spectroscopy were
unsuccessful because of problems related to
extraction of QD705 from the tissues and the
interference of fluorescence detection by
endogenous substances in the tissues. Thus, all
subsequent tissue analyses were based on ICP-
MS analyses of Cd. Contrary to its relatively
transient fate in the plasma, high levels of
QD705 persisted in the spleen, liver, and kid-
neys throughout the experimental period
(Figure 2). In the liver and kidneys (Figure 2),
there was even a tendency of increasing tissue
concentration with time. It is quite apparent
that the overall half-life of QD705 in the
body is very long, possibly in terms of weeks
if not months.
We placed each group of six mice for the
24-hr and 28-day sacrifice time points in
metabolism cages (two per cage) and per-
formed mass balance studies. The purpose
was to examine the recovery rate of the iv
dose and to calculate the proportion of
QD705 distribution in the plasma, RBCs,
liver, spleen, kidney, lung, muscle, skin, thy-
mus, fat, brain, bone, carcass, urine, and feces.
Because muscle, skin, and bones contained
very low levels of QD705, we combined their
levels into that in carcass. We chose to per-
form mass balance studies at the beginning
(1 day) and the end (28 days) of the experi-
mental duration to assess the persistence of
QD705 in the body. As shown in Figure 3A
and B, we were able to recover 100% of an iv
dose of QD705 from the body at both the 1-
and 28-day time points, indicating very little
excretion during the 28 days. Forty-four to
50% of QD705 retained in carcass mainly dis-
tributed in the large masses of muscle, skin,
and bone. QD705 also accumulated in the
liver (29.0–40.0%), spleen (4.8–5.2%), and
kidney (1.5–9.1%). There was an obvious
increase with time in the concentration of
QD705 in kidneys; a similar trend was appar-
ent in the liver although the rate of increase
was not as rapid. It is particularly interesting
to note the time-dependent tissue redistribu-
tion into the liver and kidneys, from tissue
masses in the carcass, between 1 day and
28 days (Figure 3A and B). However, QD705
was not detectable in feces and barely
detectable in the urine (0.01–0.04%). The
average recovery rate of the iv dose of QD705
was 102.2 ± 20.5% in the 1-day mass balance
study and 108.8 ± 6.1% in the 28-day mass
balance study. These results indicated that we
accounted for all the QD705 injected intra-
venously into the mice. It is important to
emphasize that essentially no excretion
occurred in 28 days. 
To assess the localization of QD705 in the
liver, spleen, and kidney, we took advantage of
the fluorescence property of QD705. These
tissues underwent the standard histologic pro-
cessing of ﬁxation, embedding in parafﬁn, and
microsection. We localized QD705 in these
tissue sections with the aid of a fluorescence
microscopy (excitation: 350–380 nm/emission
≥ 400 nm). Pathological examination revealed
marked sinusoidal congestion and increased
multinucleated giant cells in red pulps regions
(vascular areas) of the spleen. Liver and kid-
neys displayed no remarkable abnormalities
both grossly and microscopically. Tissue
localization of QD705 appeared as fine red
fluorescent granules under the fluorescence
microscope (Figure 4). Such localizations were
especially prominent at the linings of hepatic
sinusoids (Figure 4A), red pulps of spleen
(Figure 4B), renal vessels, and glomerular vas-
culature in the kidneys (Figure 4C and D).
Thus, the accumulation of QD705 in tissues
occurred consistently in vascular-rich areas. 
Discussion
In assessing the toxic potential of nanomateri-
als in general, Nel et al. (2006) excellently
summarized the potential biological and bio-
kinetic properties of nanomaterials in relation
to their physicochemical properties. These
investigators pointed out that the biological
impacts of nanomaterials are very much a
function of size, chemical composition, surface
structure, solubility, shape, and aggregation
(Nel et al. 2006). Based on the physicochemi-
cal properties of nanomaterials, as well as their
interactions with other environmental factors
such as ultraviolet (UV) activation, Nel et al.
(2006) deduced possible mechanisms by which
nanomaterials interact with biological tissues.
These include a) discontinuous crystal planes
and defects of the nanomaterials generate
active electronic configurations for electron
donors/acceptors; b) coating metals and organ-
ics create redox cycling and catalytic chemistry;
c) UV activation of electron-hole pairs leads to
bond splitting and radical formation; and
d) particle dissolution, coating, passivation,
and hydrophobicity/hydrophilicity can cause
interactions with cell membranes, cells,
and surrounding media (Nel et al. 2006).
Maysinger et al. (2006), on the other hand,
suggested that internalization of QDs by cells
could be achieved by ligand–receptor or anti-
body-mediated entry, endocytosis, electro-
poration, and oxidative damage of plasma
Tissue kinetics of QD705
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Figure 3. Mass balance studies of an iv dose of QD705 in ICR mice. Mass balance studies were carried out at 1 day (A) and 28 days (B) after dosing. Overall recov-
eries for 1 day and 28 days were, respectively, 102.2 and 108.8%.
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A Bmembrane. Whether any of these mechanisms
leads to the accumulation and redistribution
of QD705 in the spleen, liver, and kidneys in
the present study is not clear. We plan to
explore this further through additional studies
in our laboratories.
Tissue localizations of QD705 were
mainly at the linings of hepatic sinusoids, red
pulps of spleen, renal vessels, and glomerular
vasculature in the kidneys. Our observations
have the following implications: a) the visual-
ization of red ﬂuorescence (Figure 4A–C) sug-
gest aggregation of a large number of QD705
nanocrystals in situ because ﬂuorescence from
one or a few particles of QD705 would have
been invisible under the microscope; b)a
major mechanism of disposition of QD705
involves mononuclear phagocytic system and
organs. This observation is interesting because
Akerman et al. (2002) indicated that PEG
coatings on QDs were adsorption resistant
and minimized recognition by the mononu-
clear phagocytic system; and c) the congrega-
tion of QD705 in the renal vessels (Figure 4C
and D) and the continuing increase of kidney
concentration (Figure 2) would lead to further
accumulation in the glomeruli which, in turn,
would cause eventual renal toxicity. Similar
increases and accumulation with time in the
liver would similarly induce hepatotoxicity.
In conclusion, we have presented quanti-
tative time-course results from long-term
pharmacokinetic and mass balance studies of
QD705 in a common laboratory animal.
Initial ﬁndings revealed the persistent nature
of QD705 with regard to tissue kinetics. We
anticipate a very long biological half-life,
possibly in weeks or months, of QD705
nanocrystals in animals and humans. Such a
long-term accumulation in the vital organs
will most likely result in health consequences.
Because these nanocrystals are intended for
human medical use, thorough safety evalua-
tion needs to be carried out. Using this
perspective, we are expanding our pharmaco-
kinetic studies to include more thorough
plasma kinetic studies with classic pharmaco-
kinetic analyses. We are also constructing a
physiologically based pharmacokinetic model
for QD705 in mice on the basis of all the tis-
sue kinetic data and other available informa-
tion. Similarly, parallel toxicology studies
including ultrastructural examinations are in
progress. From a totally different perspective,
those chemistry colleagues who are actively
engaging in the synthesis and formulation of
QDs may wish to look into possible modiﬁca-
tions on QD705 or similar nanocrystals such
that enhanced excretion by animals, including
humans, can be achieved to optimize the
utility of a potentially very useful lines
of nanoproducts. 
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